Literature DB >> 21344746

[Epidemiology and etiology of hand-foot-and-mouth disease in Shanghai, 2009].

Zheng Teng1, Xiao-Juan Tan, Jun-Jie Shao, Yong Zhang, Xiao-Zhou Kuang, Xi Zhang, Wen-Bo Xu.   

Abstract

To analyze the epidemiological and etiological characteristics of Hand-Foot-and-Mouth disease (HFMD) in Shanghai in 2009, epidemiological data was retrieved from the National Notifiable Disease Report System (NNDRS). Nucleic acid of enterovirus (EV) was detected by real-time RT-PCR from 799 HFMD cases from 15 districts/counties in Shanghai; the complete sequences of VP1 encoding region of several identified EV71 strains and sequences of VP4 encoding region of several untyped EV were determined and analyzed. Analysis and summary of the epidemiological data was conducted with Microsoft Excel, and sequence analyses were conducted with both BioEdit and MEGA software. Untyped EV was identified through comparing the VP4 sequence to sequence database using BLAST online service. It was showed that all the 18 districts/counties had reported HFMD cases; children less than 6 years old were the most susceptible population group; the peak of epidemics of HFMD was from April to July; EV71 and Coxsackievirus A16 (CA16) were the major pathogens for this epidemic, but the constituent ratio of EV71 and CA16 was different in different months and regions; CA16 infection was mainly responsible for the mild HFMD, but EV71 for most of the severe cases; EV71 strains of Shanghai were clustered with representatives of subgenotype C4a and showed the highest identity to them, based on the sequence analyses of VP1 encoding region; 2 of the untyped EV were identified as CA2 and CA10 respectively. All the results indicated that EV71 and CA16 were the major pathogens for the epidemic of HFMD in Shanghai, 2009; the circulating EV71 belonged to subgenotype C4a. Besides, other types of EV (for example: CA2 and CA10) were also responsible for a few of the HFMD cases.

Entities:  

Mesh:

Year:  2010        PMID: 21344746

Source DB:  PubMed          Journal:  Bing Du Xue Bao        ISSN: 1000-8721


  5 in total

1.  Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line.

Authors:  Erxia Yang; Chen Cheng; Ying Zhang; Jingjing Wang; Yanchun Che; Jing Pu; Chenghong Dong; Longding Liu; Zhanlong He; Shuaiyao Lu; Yuan Zhao; Li Jiang; Yun Liao; Congwen Shao; Qihan Li
Journal:  Hum Vaccin Immunother       Date:  2014-02-28       Impact factor: 3.452

2.  Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants.

Authors:  Feng-Cai Zhu; Zheng-Lun Liang; Fan-Yue Meng; Ying Zeng; Qun-Ying Mao; Kai Chu; Xue-Fang Song; Xin Yao; Jing-Xin Li; Hong Ji; Yi-Ju Zhang; Liang Li; Hong-Xing Pan; Ke Xu; Wei-Ming Dai; Wei-Wei Zhang; Fei Deng; Hua Wang; Jun-Zhi Wang
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

3.  Association of the Polymorphism of rs1799822 on Carnitine Palmitoyltransferase II Gene with Severe Enterovirus 71 Encephalitis in Chinese Children.

Authors:  Ya Guo; Yu Zhang; Peipei Liu; Fei Li; Dandan Xin; Hongfang He; Yedan Liu; Chengqing Yang; Zongbo Chen
Journal:  J Mol Neurosci       Date:  2019-06-14       Impact factor: 2.866

4.  Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay.

Authors:  Huafei Zhang; Dong An; Wei Liu; Qunying Mao; Jun Jin; Lin Xu; Shiyang Sun; Liping Jiang; Xiaojun Li; Jie Shao; Hongxia Ma; Xueyong Huang; Shijie Guo; Haiying Chen; Tong Cheng; Lisheng Yang; Weiheng Su; Wei Kong; Zhenglun Liang; Chunlai Jiang
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

5.  Epidemiological surveillance of hand, foot and mouth disease in Shanghai in 2014-2016, prior to the introduction of the enterovirus 71 vaccine.

Authors:  Jingjing Li; Hao Pan; Xiangshi Wang; Qirong Zhu; Yanling Ge; Jiehao Cai; Yuefang Li; Aimei Xia; Jiayu Hu; Mei Zeng
Journal:  Emerg Microbes Infect       Date:  2018-03-21       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.